Cat. No. | Product name | CAS No. |
DC8301 |
Elacridar
Featured
Elacridar is an orally selectly potent P-glycoprotein (P-gp/ABCG1) inhibitor. |
143664-11-3 |
DC11192 |
Elacytarabine
Elacytarabine (CP-4055, CP4055) is a fatty acid derivative of cytarabine with potential antineoplastic activity. |
188181-42-2 |
DC3156 |
Elesclomol (STA-4783)
Featured
Elesclomol (STA-4783) is a novel potent oxidative stress inducer that illicits pro-apoptosis events among tumor cells.. |
488832-69-5 |
DC8265 |
Endoxifen
Featured
Endoxifen is a Estrogen receptor α (ERα) ligand; potent antiestrogen,an active metabolite of the cancer drug tamoxifen. |
112093-28-4 |
DC6909 |
Entinostat (MS-275)
Featured
Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM, compared with HDACs 4, 6, 8, and 10. Phase 1/2. |
209783-80-2 |
DC8300 |
Entrectinib (RXDX-101)
Featured
Entrectinib (RXDX-101), a potent and selective small molecule inhibitor of TrkA/B/C, ROS1, and ALK kinases, has demonstrated early clinical activity when orally administered intermittently under fasting conditions. |
1108743-60-7 |
DC5057 |
Enzastaurin (LY317615)
Featured
Enzastaurin (LY317615) is a potent PKCβ selective inhibitor with IC50 of 6 nM, 6- to 20-fold selectivity against PKCα, PKCγ and PKCε. Phase 3. |
170364-57-5 |
DC7927 |
EPZ011989
Featured
EPZ011989 is a potent, orally-available EZH2 Inhibitor. |
1598383-40-4 |
DC11387 |
Erdafitinib
Featured
Erdafitinib (JNJ-42756493) is a potent and orally available FGFR family inhibitor; inhibits FGFR1-4 with IC50 values of 1.2, 2.5, 3.0 and 5.7nM, respectively. |
1346242-81-6 |
DCAPI1539 |
Eribulin Mesylate
Featured
Eribulin is an anticancer drug marketed by Eisai Co. under the trade name Halaven. Eribulin is also known as E7389 and ER-086526, and also carries the US NCI designation NSC-707389. It is used to treat certain patients with breast cancer and liposarcoma. |
441045-17-6 |
DCAPI1516 |
Eribulin
Eribulin Mesylate (E7389 Mesylate), a synthetic analogue of halichondrin B in phase III clinical trials for breast cancer, binds to tubulin and microtubules. |
253128-41-5 |
DC2101 |
Erlotinib free base
Featured
Erlotinib (OSI-744; NSC 718781; R1415) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. |
183321-74-6 |
DC3139 |
Erlotinib hydrochloride
Featured
Erlotinib HCl is an HER1/EGFR inhibitor with IC50 of 2 nM. |
183319-69-9 |
DC8489 |
ETC-159
Featured
ETC-159 is a potent and specific inhibitor of Wnt secretion. ETC-159 inhibits _beta_-catenin reporter activity in a dose-dependent manner with an IC50 of 2.9 nM. |
1638250-96-0 |
DC1501 |
Everolimus
Featured
Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM. |
159351-69-6 |
DC8342 |
EW-7197
Featured
EW-7197 is a potent ALK5 inhibitor. EW-7197 showed potent in vivo anti-metastatic activity, indicating its potential for use as an anti-cancer therapy. |
1352608-82-2 |
DC11329 |
Fadrozole (hydrochloride)
Featured
Fadrozole is a non-steroidal aromatase inhibitor (IC50s = 5 and 1.4 nM for human placental and rat ovarian microsomal aromatase, respectively). |
102676-31-3 |
DC10128 |
FGF401( Roblitinib)
Featured
FGF401 is an inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. |
1708971-55-4 |
DC2014 |
Flavopiridol
Featured
Flavopiridol competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM, and CDK7 with IC50 of 300 nM. |
146426-40-6 |
DC8780 |
Flavopiridol Hydrochloride
Featured
Flavopiridol hydrochloride competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. |
131740-09-5 |
DC8164 |
Gilteritinib(ASP2215)
Featured
FLT3/AXL inhibitor |
1254053-43-4 |
DC8174 |
Pexmetinib(ARRY-614)
Featured
Pexmetinib is a potent Tie-2 and p38 MAPK dual inhibitor, with IC50s of 1 nM, 35 nM and 26 nM for Tie-2, p38α and p38β, respectively, and can be used in the research of acute myeloid leukemia. |
945614-12-0 |